CN110494451B - 靶向tim-1的嵌合抗原受体 - Google Patents

靶向tim-1的嵌合抗原受体 Download PDF

Info

Publication number
CN110494451B
CN110494451B CN201880011066.7A CN201880011066A CN110494451B CN 110494451 B CN110494451 B CN 110494451B CN 201880011066 A CN201880011066 A CN 201880011066A CN 110494451 B CN110494451 B CN 110494451B
Authority
CN
China
Prior art keywords
cells
seq
car
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880011066.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110494451A (zh
Inventor
L-Z·何
H·C·小玛什
T·凯勒
T·A·斯塔德海姆
J·M·穆拉德
J·雷德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CELDARA MEDICAL LLC
Celldex Therapeutics Inc
Original Assignee
CELDARA MEDICAL LLC
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CELDARA MEDICAL LLC, Celldex Therapeutics Inc filed Critical CELDARA MEDICAL LLC
Publication of CN110494451A publication Critical patent/CN110494451A/zh
Application granted granted Critical
Publication of CN110494451B publication Critical patent/CN110494451B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880011066.7A 2017-01-13 2018-01-12 靶向tim-1的嵌合抗原受体 Active CN110494451B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445976P 2017-01-13 2017-01-13
US62/445,976 2017-01-13
PCT/US2018/013551 WO2018132695A1 (en) 2017-01-13 2018-01-12 Chimeric antigen receptors targeting tim-1

Publications (2)

Publication Number Publication Date
CN110494451A CN110494451A (zh) 2019-11-22
CN110494451B true CN110494451B (zh) 2023-12-01

Family

ID=62840504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880011066.7A Active CN110494451B (zh) 2017-01-13 2018-01-12 靶向tim-1的嵌合抗原受体

Country Status (5)

Country Link
US (2) US11541076B2 (enExample)
EP (1) EP3568416A4 (enExample)
JP (1) JP7303749B2 (enExample)
CN (1) CN110494451B (enExample)
WO (1) WO2018132695A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064076A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
DK3688032T3 (da) 2017-09-26 2025-12-15 Cero Therapeutics Holdings Inc Kimære engulfment-receptormolekyler og anvendelsesfremgangsmåder
RU2020135107A (ru) 2018-03-28 2022-04-29 Серо Терапьютикс, Инк. Клеточные иммунотерапевтические композиции и их применения
US12291557B2 (en) 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof
US12448426B2 (en) * 2018-05-17 2025-10-21 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
AU2019314452B2 (en) * 2018-08-02 2022-12-08 Kite Pharma, Inc Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof
KR102879284B1 (ko) 2018-08-29 2025-10-31 난징 레전드 바이오테크 씨오., 엘티디. 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
US20220144960A1 (en) 2018-12-26 2022-05-12 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
WO2020227446A1 (en) * 2019-05-07 2020-11-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
US20220265715A1 (en) * 2019-07-24 2022-08-25 Eureka Therapeutics, Inc. Chimeric antigen receptor t cells and uses thereof
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
WO2021130535A2 (en) * 2019-12-28 2021-07-01 Shanghai Cell Therapy Group Company Co., Ltd. Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules
CN115698285A (zh) * 2020-02-14 2023-02-03 小利兰·斯坦福大学董事会 具有cd2激活的嵌合抗原受体
GB202004371D0 (en) * 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
US11707487B2 (en) * 2020-04-13 2023-07-25 Affyimmune Therapeutics, Inc. EpCAM antibody and CAR-T cells
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
WO2021249384A1 (en) * 2020-06-09 2021-12-16 Hangzhou Leading Edge Pharmaceutical Ltd. Compositions and methods for enhancing immune response
CN112063588A (zh) * 2020-08-13 2020-12-11 南京北恒生物科技有限公司 工程化免疫细胞及其用途
JP7868033B2 (ja) 2020-08-14 2026-06-01 セロ・セラピューティクス・ホールディングス・インコーポレイテッド キメラｔｉｍ受容体およびその使用
JP2023541253A (ja) * 2020-09-10 2023-09-29 ムスタング バイオ，インコーポレイテッド 癌標的のｃａｒ－ｔ細胞を含む併用療法と、それを癌治療に使用する方法
AU2021360477A1 (en) * 2020-10-13 2023-06-15 The Trustees Of The University Of Pennsylvania In vivo targeting of t cells for mrna therapeutics
CN112830974B (zh) * 2021-01-08 2022-07-26 深圳市珈钰生物科技有限公司 一种嵌合抗原受体、载体、人树突状细胞、细胞系、实体肿瘤治疗药物及制备方法和应用
CN114149505B (zh) * 2021-01-12 2022-11-04 北京门罗生物科技有限公司 治疗b细胞相关疾病的免疫细胞、制备方法及其应用
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用
US20250304915A1 (en) * 2021-05-25 2025-10-02 Institut Curie Myeloid Cells Overexpressing BCL2
CN115521917A (zh) * 2021-06-25 2022-12-27 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN113583122B (zh) * 2021-07-29 2023-08-29 武汉华美生物工程有限公司 抗人sema4d抗体及其制备方法和应用
CN115322257B (zh) * 2021-08-16 2023-05-30 上海优替济生生物医药有限公司 Bcma靶向抗体、嵌合抗原受体及其应用
CA3233096A1 (en) * 2021-10-20 2023-04-17 Board Of Regents, The University Of Texas System Engineering nk cells with a car construct with optimal signaling
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
CN115974976B (zh) * 2022-11-23 2024-06-04 华中科技大学 拮抗多肽及用于制备抗急性肾损伤药物的应用
US20250092362A1 (en) * 2023-09-15 2025-03-20 Terumo Bct, Inc. System And Methods For Producing Chimeric Antigen Receptor Cells
CN119409822B (zh) * 2024-11-01 2026-02-17 中国科学技术大学 抗体或其抗原结合片段及其应用
WO2026105018A1 (en) * 2024-11-12 2026-05-21 Dana-Farber Cancer Institute, Inc. Bak1/bax knockout in car-t cells, methods, uses, and compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059082A1 (en) * 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
AU2003228336B2 (en) 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US9845362B2 (en) * 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20150110792A1 (en) * 2011-11-22 2015-04-23 Biogen Idec Ma Inc. ANTI-TIM-1 Antibodies And Uses Thereof
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
CA2913052A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
EP2939690A1 (en) * 2014-04-29 2015-11-04 Medizinische Hochschule Hannover Vaccine
CA2965224A1 (en) * 2014-10-24 2016-04-28 Bcrt Holding Bv T cell-based immunotherapeutics
US11459390B2 (en) * 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016168595A1 (en) * 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059082A1 (en) * 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof

Also Published As

Publication number Publication date
CN110494451A (zh) 2019-11-22
US11541076B2 (en) 2023-01-03
JP2020513839A (ja) 2020-05-21
EP3568416A4 (en) 2020-07-08
JP7303749B2 (ja) 2023-07-05
US20190336534A1 (en) 2019-11-07
US20230355673A1 (en) 2023-11-09
WO2018132695A1 (en) 2018-07-19
EP3568416A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
US20230355673A1 (en) Chimeric antigen receptors targeting tim-1
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US11242376B2 (en) Compositions and methods for TCR reprogramming using fusion proteins
CN115052902B (zh) 淋巴细胞-抗原提呈细胞共刺激因子及其应用
KR102821235B1 (ko) 선택적 단백질 발현을 위한 조성물 및 방법
EP3298033B2 (en) Compositions and medical uses for tcr reprogramming using fusion proteins
KR102859548B1 (ko) 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
AU2016297014B2 (en) Methods for improving the efficacy and expansion of immune cells
KR20200069358A (ko) 키메라 항원 수용체 발현 세포의 제조 방법
KR20250061769A (ko) 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
CN113061580A (zh) 一种经修饰的免疫效应细胞及其制备方法
AU2025279705A1 (en) Combination therapy using a chimeric antigen receptor
US20210187022A1 (en) Engineered t cells for the treatment of cancer
KR102960041B1 (ko) Egfr 양성 암을 치료하기 위한 조성물 및 방법
JP2025066746A (ja) 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
CN114729059A (zh) 包含前列腺干细胞抗原(psca)嵌合抗原受体(cars)的组合物和方法
CN120265660A (zh) 新型cd19靶向多肽和cd19定向免疫疗法
WO2025016450A1 (en) Combination of cldn18.2 and gucy2c targeted antagonist therapy
RU2841244C2 (ru) Химерные антигенные рецепторы и пути их применения
RU2843842C1 (ru) Композиции и способы для лечения egfr-положительных форм рака
HK40045811A (en) Compositions and methods for tcr reprogramming using fusion proteins
HK40008051A (en) Compositions and methods for tcr reprogramming using fusion proteins
HK40010509A (en) Engineered t cells for the treatment of cancer
HK1252643B (en) Compositions and medical uses for tcr reprogramming using fusion proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant